Hypertension in COVID-19, A Risk Factor for Infection or A Late Consequence?

Area of Science:

• Cardiovascular Medicine
• Infectious Diseases
• Pathophysiology

Background:

• Hypertension (HTN) is frequently correlated with increased morbidity and mortality in SARS-CoV-2 infected patients.
• SARS-CoV-2 interacts with host cells via the angiotensin-converting enzyme 2 (ACE2) receptor, influencing the renin-angiotensin system (RAS).
• The RAS exhibits dual roles: pro-inflammatory (ACE/Ang II/AT1R) and anti-inflammatory (ACE2/Ang1-7/Mas axis).

Purpose of the Study:

• To elucidate the pathophysiology of newly diagnosed hypertension in the context of COVID-19.
• To analyze the impact of this newly diagnosed HTN on morbidity outcomes in COVID-19 patients.

Main Methods:

• Review and discussion of existing data on SARS-CoV-2 and hypertension.
• Analysis of the molecular mechanisms involving the renin-angiotensin system (RAS) in COVID-19 pathophysiology.
• Correlation of newly diagnosed hypertension with COVID-19 morbidity.

Main Results:

• SARS-CoV-2 infection modulates the RAS, potentially exacerbating hypertension.
• The interplay between SARS-CoV-2 and the RAS influences inflammatory responses and disease severity.
• Newly diagnosed hypertension may represent a significant factor affecting COVID-19 patient morbidity.

Conclusions:

• Understanding the interaction between SARS-CoV-2 and the RAS is crucial for managing COVID-19 patients with hypertension.
• Further research is needed to clarify the specific pathways driving morbidity in COVID-19 patients with newly diagnosed HTN.
• This pathophysiology discussion highlights potential therapeutic targets within the RAS for improved COVID-19 outcomes.